Medical devices — US PTAB Patent Cases
376 decisions indexed
Page 8 of 13 · 376 total
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical has filed a petition for inter partes review of Spinelogik’s U.S. Patent 8,460,385 covering a spinal fusion device. The challenger asserts that the claims are obvious over prior‑art implants (Moskowitz, Hess) and a combination with Steffee’s curved fasteners, and seeks cancellation of claims 1‑5, 7 and 9.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully petitioned the PTAB to challenge Spinelogik's spinal fusion implant patents. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over prior art references like Blain. This decision advances the dispute into active trial proceedings.
Garmin International, Inc. v.Cardiacsense LTD
Garmin and Cardiacsense settled their IPR dispute over patent 7,980,998, leading the PTAB to terminate the proceeding without a final decision.
Garmin International, Inc. v.Cardiacsense LTD
Garmin and CardiacSense have settled their IPR dispute over U.S. Patent 7,980,998 and jointly request the Board keep the settlement agreement confidential, effectively moving to terminate the proceeding.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed filed a Request for Director Review seeking reversal of the PTAB’s denial to institute an IPR on its PAP device patent. The petitioner contends the Board misapplied General Plastic, contrary to recent Director guidance. The request emphasizes different prior art and the need for efficient review of related patents.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed seeks a PTAB waiver of the 30‑day deadline to request Director Review after the Board denied institution of its IPR, citing a conflicting Director decision and the need for consistency across related petitions.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed’s request to waive the deadline for a Director Review of its IPR petition was met with a detailed opposition from Cleveland Medical Devices, which argues no good cause exists and cites Board precedent. The patent owner urges denial of the waiver, emphasizing procedural rules and lack of new discretionary factors.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed filed a request to waive the 30‑day deadline for a Director Review in its IPR against Cleveland Medical Devices. The Board has set a five‑day window for the patent owner to respond, limiting the reply to five pages and prohibiting new evidence.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed has filed a petition for inter partes review of Cleveland Medical Devices' ’284 patent covering a networked PAP therapy system, arguing that the claims are obvious over prior PAP and telemedicine technologies.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB denied ResMed Corp.'s Inter Partes Review petition against Cleveland Medical Devices' patent, citing prior filings and concerns over 'road-mapping'.
Catalyst OrthoScience Inc. v.Shoulder Innovations, Inc.
The PTAB denied Catalyst OrthoScience's Post-Grant Review of Shoulder Innovations' reverse shoulder implant patent (12,023,254). The denial was based on the advanced stage and significant overlap with co-pending district court litigation.
LifeScan, Inc. et al. v.Cellspin Soft, Inc.
The PTAB granted a sua sponte Director review of several IPRs involving LifeScan and TikTok after rejecting the patent owner’s motion to terminate on RPI and sovereign‑person grounds. The IPRs are stayed pending the Director’s opinion.
Arthrex, Inc. et al. v.Medshape, Inc.
Arthrex has filed an IPR petition seeking to invalidate ten claims of Medshape’s ’222 bone‑fixation patent, arguing obviousness over Monassevitch and over a Bolesky‑Hoffman combination. The petition also argues the Board should not deny institution under §314.
Arthrex, Inc. et al. v.Medshape, Inc.
The PTAB denied Arthrex's IPR petition against Medshape's patent (7985222), citing the complex and overlapping nature of co-pending district court litigation.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have entered a confidential settlement and jointly moved to terminate IPR2024-00891 covering U.S. Patent No. 11,020,031. The motion cites 35 U.S.C. §317(a) and notes that the Board has not yet decided the merits. The parties also seek termination of related IPRs and a district‑court case.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have jointly filed a request with the PTAB to keep their settlement agreement confidential, invoking statutory provisions for business‑confidential treatment.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom settled their dispute over U.S. Patent 11,020,031 B1. The PTAB granted a joint motion to terminate the IPR and ordered the settlement agreement to be kept confidential.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. successfully secured institutional status in an IPR against DexCom, Inc., regarding continuous glucose monitoring systems. The Board found sufficient evidence that prior art references anticipate or render obvious key claims related to transcutaneous sensors and drift profiles.
BTL Industries, Inc. v.InMode Ltd.
ThermiGen settled its patent infringement lawsuit with Viveve Medical, securing a non‑exclusive license and agreeing to pay royalties. The settlement resolves the 2016 litigation and allows Thermi to continue developing its temperature‑controlled RF platforms for women's intimate health.
BTL Industries, Inc. v.InMode Ltd.
BTL Industries successfully navigated the institution phase of an IPR against InMode Ltd.'s medical device patent (8961511). The Board adopted a specialized skill level for the POSA and preliminarily constructed key terms related to RF energy application in gynecological tissue.
BTL Industries, Inc. v.InMode Ltd.
The PTAB issued a final written decision rejecting all 58 claims of the patent owner's application. The Board found that the Petitioner failed to meet its burden of proof regarding obviousness over combinations of prior art references (Edwards, Mosher, Ingle, Ollivier).
Eunsung Global Corp. v.HydraFacial LLC et al.
HydraFacial LLC opposes Eunsung Global Corp.’s request for Director Review, asserting the Board properly denied institution under Fintiv factors and that the petitioner’s new arguments are untimely. The Patent Owner urges the Director to deny the request.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. seeks Director Review of the PTAB’s denial to institute an IPR against HydraFacial’s hydrodermabrasion patent, arguing misapplication of Fintiv factors and the need for efficient resolution of multiple lawsuits.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. has filed an IPR petition seeking cancellation of 41 claims of HydraFacial's skin‑treatment patent, arguing obviousness over four prior‑art references. The petition asserts that the examiner never considered the Karasiuk‑Palmer, Greenberg, and Trueba teachings and that discretionary denial is not warranted.
Eunsung Global Corp. v.HydraFacial LLC et al.
The PTAB denied institution for an IPR challenge regarding skin treatment systems due to substantial overlap with parallel ITC proceedings and advanced litigation. This decision emphasizes resource conservation when multiple venues address the same prior art.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody, Inc. successfully convinced the PTAB to institute proceedings against Hyperice IP Subco, LLC regarding a medical device patent (11857482). The Board found prima facie evidence of obviousness and indefiniteness across multiple claims based on prior art combinations.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody challenged Hyperice's patent on percussive massagers based on indefiniteness and obviousness, but the PTAB upheld the claims. The Board found that key terms like 'substantially cylindrical' were supported by functional limitations in the specification.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom filed a joint request with the PTAB to keep their settlement agreement confidential under statutory and regulatory provisions.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care and DexCom have filed a joint motion to terminate IPR2024-00859 under 35 U.S.C. §317(a) after reaching a confidential settlement and patent license agreement.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care Inc. challenged DexCom, Inc.'s '625 patent claims in a PTAB proceeding, asserting that the claims are obvious under 35 U.S.C. § 103. The petitioner argues that numerous features of the patented technology are rendered obvious either by single prior art references (Rao) or combinations involving Rao and Lundquist. Additionally, Abbott questions the written description support for key anti-rotation features.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.